Accepted for Publication: September 2, 2014.
Published Online: November 10, 2014. doi:10.1001/jamaneurol.2014.2137.
Study concept and design: Flanagan, Lucchinetti, Pittock.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Flanagan, Pittock.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Flanagan, Lucchinetti, Horta.
Obtained funding: Jiao, Pittock.
Administrative, technical, or material support: Jiao, Horta, Pittock.
Study supervision: Pittock.
Conflict of Interest Disclosures: Dr Weinshenker received a research grant from the Guthy-Jackson Foundation. He receives royalties from RSR Ltd for a technology license related to a test for aquaporin-4 autoantibodies for diagnosis of neuromyelitis optica. He serves on data safety monitoring committees for Novartis, Biogen Idec, and Mitsubishi Pharmaceutical and serves on an adjudication panel for Medimmune Pharmaceuticals. He served as a consultant for GlaxoSmithKline, Elan, Ono, Chugai, and Alexion Pharmaceuticals; and he serves on the editorial boards for Neurology, the Canadian Journal of Neurological Sciences, and the Turkish Journal of Neurology. Dr Lennon receives royalties for technology relating to aquaporin-4 antibodies for diagnosis of neuromyelitis optica and is a named inventor on filed patents that relate to functional aquaporin-4/neuromyelitis optica–IgG assays and neuromyelitis optica–IgG as a cancer marker. Dr Lucchinetti shares in royalties from the marketing of kits detecting aquaporin-4 autoantibodies and from the sale of Blue Books of Neurology: Multiple Sclerosis 3 (Saunders Elsevier, 2010). Dr Wingerchuk has received research support from Alexion and TerumoBCT; has served as a consultant to Alexion, MedImmune, and Chugai Pharmaceuticals; and has received financial compensation for service on an adjudication committee for a MedImmune clinical trial. Dr Shuster received compensation for PRIME Continuing Medical Education in September 2012. Dr Pittock is a named inventor on patents that relate to functional aquaporin-4/neuromyelitis optica–IgG assays and neuromyelitis optica–IgG as a cancer marker and has provided consultation to Alexion Pharmaceuticals, MedImmune LLC, and Chugai Pharma but has received no personal fees or personal compensation for these consulting activities. Funding for this study was provided by Alexion Pharmaceuticals Inc. All compensation for consulting activities was paid directly to Mayo Clinic. No other disclosures were reported.
Funding/Support: Funding was provided by the Guthy-Jackson Charitable Foundation, grant RG 3185B3 (Dr Lucchinetti) from the National Multiple Sclerosis Society, and grants NS065829 (Drs Lennon and Pittock) and NS49577-R01 (Dr Lucchinetti) from the National Institutes of Health.
Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.